Safety blood results across baseline, placebo, testosterone arms and the OLE.
ADVERSE EVENTS
NA = not available and is also utilised when an individual withdrew from the trial. The highlighted numbers are listed as adverse events. The trial has been split into baseline, placebo and testosterone arms. Placebo = placebo phase, when the participants were provided with the placebo (either 0–12 weeks or 14–26 weeks depending on the participant). Testosterone = testosterone phase, when the participans were provided with testosterone (either 0–12 weeks or 14–26 weeks depending on the participant). The 6 months and 12 months columns refers to the OLE 6 month and 12 month time periods.